Tumor Necrosis Factor (TNF) Inhibitors Market
Tumor Necrosis Factor (TNF) Inhibitors Market Analysis By Drug Class (Adalimumab, Infliximab, Rituximab), By Indication (Rheumatoid Arthritis, Crohn's Disease, Psoriasis), By Distribution Channel & By Region - Global Forecast 2021 to 2027
Analysis of Tumor Necrosis Factor (TNF) Inhibitors market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Tumor Necrosis Factor (TNF) Inhibitors Market Outlook (2021 to 2027)
Consumption of tumor necrosis factor inhibitors is expected to rise at a CAGR of 1.3% from 2021 to 2027. In 2020, the global tumor necrosis factor (TNF) inhibitors market was valued at US$ 41.6 Bn, and is anticipated to reach a valuation of US$ 45.5 Bn by the end of 2027.
| Report Attributes | Details |
|---|---|
| Tumor Necrosis Factor Inhibitors Market Size (2020) | US$ 41.6 Bn |
| Projected Year Value (2027) | US$ 45.5 Bn |
| Global Market Growth Rate (2021 to 2027) | 1.3% CAGR |
| China Market Growth Rate (2021 to 2027) | 2.7% |
| Key Companies Profiled | AbbVie Inc.; Amgen Inc.; Innovent Biologics, Inc.; Novartis International AG; Pfizer, Inc.; Merck & Co., Inc.; Biocad Biopharmaceutical Co.; Boehringer Ingelheim Pharmaceuticals, Inc. |
Demand for the adalimumab drug class is projected to increase at the highest CAGR from 2021 to 2027. Rising R&D expenditure on adalimumab drugs are driving market growth.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Tumor Necrosis Factor Inhibitors from 2017 to 2020 Vs Market Outlook for 2021 to 2027
“Rising Prevalence of Autoimmune Diseases to Boost Market Revenue”
As per Fact.MR, a market research and competitive intelligence provider, the global tumor necrosis factor inhibitors market was valued at US$ 41.6 Bn in 2020.
TNF inhibitors are medications that stop the body's physiologic response to tumor necrosis factors, such as the inflammatory response generated by TNF cytokines. Inflammation in the body is caused by TNF-alpha, a crucial component of the autoimmune system.
The market for tumor necrosis factor inhibitors is reaching new heights as the global healthcare industry grows. Tumor necrosis factor blockers are a type of anti-inflammatory drug that is routinely prescribed. Antibodies from human or animal tissues are used to make tumor necrosis factor inhibitor drugs, which are used to treat chronic diseases.
Growing prevalence of autoimmune illnesses such as (RA) rheumatoid arthritis, psoriasis, inflammatory bowel disorder, and Crohn's disease, as well as the increase in the elderly population, are the primary reasons driving the market expansion.
The TNF inhibitors market is projected to expand at a CAGR of 1.3% from 2021 to 2027.
Which Key Dynamics are Boosting Sales of Tumor Necrosis Factor Inhibitors?
“Advanced Healthcare Facilities & Rapid Deployment of TNF Inhibitor Biosimilars”
The global population is increasingly ageing, especially in developed countries like the United States, Japan, and Western Europe. Developed countries have a higher rate of ageing than undeveloped countries. This is due to the continually improving health infrastructure, reimbursement mechanisms, and innovations in healthcare facilities in these countries.
Furthermore, the availability of a variety of TNF blocker drugs has increased. As a result, people's life expectancies have increased. Tumor necrosis factor inhibitors are popular among the elderly since they help them live longer and healthier lives.
An increase in the number of elderly people leads to a higher risk of sickness, which is expected to drive rising demand for tumor necrosis factor-alpha blockers globally over the coming years.
TNF inhibitor biosimilars are likely to gain market share over the projection period as a result of increased patient affordability in low-income countries and growing patient awareness about the same.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Roadblocks are Being Faced by Tumor Necrosis Factor Inhibitor Manufacturers?
“High Cost of Tumor Necrosis Inhibitor Drugs & Increase in Alternative Options Restraining Industry Growth”
High production cost of tumor necrosis factor medications, as well as a lack of R&D initiatives, are projected to impede market expansion. The market for tumor necrosis factor inhibitors is expected to be challenged by a rise in the preference for alternative therapies over the forecast period.
The market for TNF inhibitors is predicted to be limited by the negative side effects of inhibitor drugs on patients. Injection site responses, neutropenia, infusion reactions, and infections are among the numerous side effects of TNF inhibition that have been observed in clinical studies and post-marketing surveillance.
The aforementioned factors are expected to limit the global tumor necrosis factor inhibitors market growth over the forecast period.
Which Region is Projected to Offer Lucrative Opportunity for Tumor Necrosis Factor Inhibitor Suppliers?
“Presence of Advanced Healthcare Infrastructure to Propel Market Expansion in North America”
North America is likely to maintain its dominance in the global tumor necrosis factor inhibitors market over the forecast period due to increased development and launches of new medicines in the region.
Presence of superior healthcare infrastructure, a rising frequency of autoimmune disorders in the population, and favorable reimbursement policies are all factors promoting market expansion in North America.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
How Will the TNF Inhibitors Market Perform in the U.S.?
“Huge Investments by Key Players for Novel Drugs Development Boosting Market Growth”
The U.S. tumor necrosis factor inhibitors market was valued at US$ 11.3 Bn in 2020 and is projected to increase at the highest CAGR over the forecast period. Because of the USFDA's fast drug approval effort, the U.S. has the biggest market share.
Rising prevalence of inflammatory bowel disease (IBD), increasing demand for TNF drugs, and the growing preference for biosimilars are driving the market growth in the U.S. Huge investments by leading players, as well as increase in R&D efforts, are likely to account for a considerable portion of market revenue over the forecast period.
Why is Demand for Tumor Necrosis Factor Inhibitors Rising in China?
“Proactive Government Initiatives Driving Market Growth”
China is projected to garner a market value of US$ 8.5 Bn by 2027, expanding at a 2.7% CAGR from 2021 to 2027. The China TNF inhibitors market is being driven by the presence of prominent manufacturers, proactive government measures, and the rise in the older population.
Rising rheumatic disease occurrences, improved awareness of the efficacy and availability of TNF inhibitors, higher investments in biosimilars by various industrial companies, and increased regulatory board support for biosimilar approval are projected to stimulate overall market expansion in China.
Category-wise Insights
Which Drug Class Will Hold a Dominant Market Share?
“Growing Usage of Adalimumab for Wide Range of Inflammatory Disorders Treatment”
Adalimumab is expected to have the largest market share in the drug class segment over the forecast period. Under the commercial name Humira, adalimumab is the first and only completely human monoclonal antibody licenced by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.
Adalimumab is a drug that is used to treat a wide range of inflammatory disorders in both adults and children, including those that are associated with autoimmune diseases. The activation of a protein called TNF in people with autoimmune disease causes inflammation, which can cause painful and uncomfortable joint swelling, damage, and other forms of inflammation.
Adalimumab is an FDA-approved medication for the treatment of inflammatory autoimmune disorders. Adalimumab is an anti-inflammatory medication used to treat rheumatoid arthritis in people who have moderate to severe symptoms. It works by locating and reducing the source of inflammation that causes joint pain and damage.
Which Indication is Driving Most Demand for TNF Inhibitors?
“Increasing Need for Rheumatoid Arthritis Treatment Driving Demand for TNF Inhibitor Drugs”
Rheumatoid arthritis holds a significant market share of the tumor necrosis factor inhibitors market because of its widespread prevalence. Rheumatoid arthritis (RA) is a long-term inflammatory disorder of the joints. Inflammation may cause problems with the function and appearance of joints and other body parts. The joints of the fingers of the hand can become dysfunctional as a result of RA.
Rheumatoid arthritis has the highest market share because of rising incidence rates, increased awareness, and a high treatment rate, and it is expected to continue its position with significant growth over the forecast period.
Moreover, RA is more common in women than in men, is predicted to account for around two-thirds of the overall patient population with arthritis, and it worsens with age, all of which are expected to move the market forward.
Competitive Landscape
Tumor necrosis factor inhibitor providers are focused on the advancement and production of new products. To minimize side effects, increase their market share, and achieve traction in the global marketplace, market players are developing products using chemically stable ingredients.
For instance :
- In December 2021, Rinvoq, an AbbVie medication, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with active psoriatic arthritis.
Key Segments Covered in TNF Inhibitors Industry Research
-
By Drug Class :
- Adalimumab
- Infliximab
- Rituximab
- Others
-
By Indication :
- Rheumatoid Arthritis
- Crohn's Disease
- Psoriasis
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
-
By Region :
- North America TNF Inhibitors Market
- Europe TNF Inhibitors Market
- Asia Pacific TNF Inhibitors Market
- Latin America TNF Inhibitors Market
- MEA TNF Inhibitors Market
Table of Content
- 1. Global Market - Executive Summary
- 2. Global Market Overview
- 3. Market Risks and Trends Assessment
- 4. Market Background and Foundation Data Points
- 5. Global Market Demand (US$ Mn) Analysis 2017 to 2020 and Forecast, 2021 to 2027
- 6. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, By Drug Class
- 6.3.1. Adalimumab
- 6.3.2. Infliximab
- 6.3.3. Rituximab
- 6.3.4. Others
- 7. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, By Indication
- 7.3.1. Rheumatoid Arthritis
- 7.3.2. Crohn's Disease
- 7.3.3. Psoriasis
- 7.3.4. Others
- 8. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Specialty Pharmacies
- 8.3.3. Online Pharmacies
- 9. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, By Region
- 9.3.1. North America
- 9.3.2. Latin America
- 9.3.3. Europe
- 9.3.4. East Asia
- 9.3.5. South Asia & Oceania
- 9.3.6. Middle East and Africa (MEA)
- 10. North America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 11. Latin America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 12. Europe Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 13. East Asia Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 14. South Asia & Oceania Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 15. Middle East and Africa Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 16. Market Structure Analysis
- 17. Competition Analysis
- 17.4. AbbVie Inc.
- 17.5. Amgen Inc.
- 17.6. Innovent Biologics, Inc.
- 17.7. Novartis International AG
- 17.8. Pfizer, Inc.
- 17.9. Merck & Co., Inc.
- 17.10. Biocad Biopharmaceutical Co.
- 17.11. Boehringer Ingelheim Pharmaceuticals, Inc.
- 18. Assumptions And Acronyms Used
- 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 2: Global Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 3: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 4: Global Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 5: Global Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 6: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 7: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 8: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 9: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2017 to 2020
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2021 to 2027
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2021 to 2027
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 16: North America Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 17: North America Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 19: North America Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 20: North America Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 28: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 29: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 31: Latin America Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 32: Latin America Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 37: Europe Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 38: Europe Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 39: Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 40: Europe Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 41: Europe Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 42: Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 43: Europe Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 44: Europe Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 45: Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 46: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 47: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 48: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 49: East Asia Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 50: East Asia Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 52: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 53: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 55: East Asia Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 56: East Asia Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 57: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 58: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 59: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 60: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 61: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 62: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 63: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 64: South Asia & Oceania Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 65: South Asia & Oceania Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 66: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 67: South Asia & Oceania Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 68: South Asia & Oceania Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 69: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 70: South Asia & Oceania Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 71: South Asia & Oceania Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 72: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
Table 73: MEA Market Value (US$ Mn) Analysis, by Country, 2017 to 2020
Table 74: MEA Market Value (US$ Mn) Analysis, by Country, 2021 to 2027
Table 75: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2021 to 2027
Table 76: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2017 to 2020
Table 77: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2021 to 2027
Table 78: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2021 to 2027
Table 79: MEA Market Value (US$ Mn) Analysis, by Indication, 2017 to 2020
Table 80: MEA Market Value (US$ Mn) Analysis, by Indication, 2021 to 2027
Table 81: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2021 to 2027
Table 82: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2017 to 2020
Table 83: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2021 to 2027
Table 84: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2021 to 2027
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 2: Global Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 3: Global Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 4: Global Market Incremental $ Opportunity, 2021 to 2027
Figure 5: Global Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 6: Global Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 7: Global Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 8: Global Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 9: Global Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 10: Global Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 14: Global Market Share and BPS Analysis by Region, 2021 & 2027
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2021 to 2027
Figure 16: Global Market Attractiveness Analysis by Region, 2021 to 2027
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 20: North America Market Incremental $ Opportunity, 2021 to 2027
Figure 21: North America Market Share Analysis by Country, 2021 & 2027
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 23: North America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 24: North America Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 25: North America Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 27: North America Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 28: North America Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 29: North America Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 36: Latin America Market Incremental $ Opportunity, 2021 to 2027
Figure 37: Latin America Market Share Analysis by Country, 2021 & 2027
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 39: Latin America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 40: Latin America Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 41: Latin America Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 42: Latin America Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 43: Latin America Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 44: Latin America Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 45: Latin America Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 49: Europe Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 50: Europe Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 51: Europe Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 52: Europe Market Incremental $ Opportunity, 2021 to 2027
Figure 53: Europe Market Share Analysis by Country, 2021 & 2027
Figure 54: Europe Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 55: Europe Market Attractiveness Analysis by Country, 2021 to 2027
Figure 56: Europe Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 57: Europe Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 58: Europe Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 59: Europe Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 60: Europe Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 61: Europe Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 62: Europe Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 63: Europe Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 64: Europe Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 65: East Asia Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 66: East Asia Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 67: East Asia Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 68: East Asia Market Incremental $ Opportunity, 2021 to 2027
Figure 69: East Asia Market Share Analysis by Country, 2021 & 2027
Figure 70: East Asia Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 71: East Asia Market Attractiveness Analysis by Country, 2021 to 2027
Figure 72: East Asia Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 73: East Asia Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 74: East Asia Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 75: East Asia Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 76: East Asia Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 77: East Asia Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 78: East Asia Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 79: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 80: East Asia Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 81: South Asia & Oceania Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 82: South Asia & Oceania Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 83: South Asia & Oceania Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 84: South Asia & Oceania Market Incremental $ Opportunity, 2021 to 2027
Figure 85: South Asia & Oceania Market Share Analysis by Country, 2021 & 2027
Figure 86: South Asia & Oceania Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 87: South Asia & Oceania Market Attractiveness Analysis by Country, 2021 to 2027
Figure 88: South Asia & Oceania Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 89: South Asia & Oceania Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 90: South Asia & Oceania Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 91: South Asia & Oceania Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 92: South Asia & Oceania Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 93: South Asia & Oceania Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 94: South Asia & Oceania Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 95: South Asia & Oceania Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 96: South Asia & Oceania Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Figure 97: MEA Market Value (US$ Mn) Historical Analysis, 2017 to 2020
Figure 98: MEA Market Value (US$ Mn) Forecast and Analysis, 2021 to 2027
Figure 99: MEA Market Value Y-o-Y Growth and Forecast, 2017 to 2027
Figure 100: MEA Market Incremental $ Opportunity, 2021 to 2027
Figure 101: MEA Market Share Analysis by Country, 2021 & 2027
Figure 102: MEA Market Y-o-Y Growth Projection by Country, 2021 to 2027
Figure 103: MEA Market Attractiveness Analysis by Country, 2021 to 2027
Figure 104: MEA Market Share and BPS Analysis by Drug Class, 2021 & 2027
Figure 105: MEA Market Y-o-Y Growth Projections by Drug Class, 2021 to 2027
Figure 106: MEA Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 107: MEA Market Share and BPS Analysis by Indication, 2021 & 2027
Figure 108: MEA Market Y-o-Y Growth Projections by Indication, 2021 to 2027
Figure 109: MEA Market Attractiveness Analysis by Indication, 2021 to 2027
Figure 110: MEA Market Share and BPS Analysis by Distribution Channel, 2021 & 2027
Figure 111: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2027
Figure 112: MEA Market Attractiveness Analysis by Distribution Channel, 2021 to 2027
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the market value for tumor necrosis factor inhibitors in 2021?
The global tumor necrosis factor inhibitors market was valued at US$ 42.1 Bn in 2021.
What are the key market statistics for tumor necrosis factor inhibitors in Germany?
The Germany TNF inhibitors market in is expected to exhibit 0.4% CAGR over the forecast period.
Which growth trends are driving demand growth of tumor necrosis factor inhibitors market?
Increasing prevalence of autoimmune disorders, new product launches of biosimilars, and rise in the geriatric population are driving market growth
What is the projected growth rate for the global TNF inhibitors market?
The global tumor necrosis factor inhibitors market is expected to rise at a 1.3% CAGR from 2021 to 2027.
Which 5 countries drive most demand for TNF inhibitors?
The U.S., Canada, Japan, China, and Germany are expected to drive most demand for tumor necrosis factor inhibitors.
Who are the key tumor necrosis factor inhibitor suppliers?
AbbVie Inc., Amgen Inc., Innovent Biologics, Inc., Novartis International AG, and Pfizer, Inc. are key tumor necrosis factor inhibitor suppliers.
Tumor Necrosis Factor (TNF) Inhibitors Market